Atogepant, the first oral preventive treatment for chronic migraine
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
Atogepant, the first oral preventive treatment for chronic migraine. / Haanes, Kristian A.; Edvinsson, Lars.
I: The Lancet, Bind 402, Nr. 10404, 2023, s. 748-749.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Haanes, KA & Edvinsson, L 2023, 'Atogepant, the first oral preventive treatment for chronic migraine', The Lancet, bind 402, nr. 10404, s. 748-749. https://doi.org/10.1016/S0140-6736(23)01462-9
APA
Haanes, K. A., & Edvinsson, L. (2023). Atogepant, the first oral preventive treatment for chronic migraine. The Lancet, 402(10404), 748-749. https://doi.org/10.1016/S0140-6736(23)01462-9
Vancouver
Haanes KA, Edvinsson L. Atogepant, the first oral preventive treatment for chronic migraine. The Lancet. 2023;402(10404):748-749. https://doi.org/10.1016/S0140-6736(23)01462-9
Author
Bibtex
@article{ab051747e3c5449391d95b1e5afe888b,
title = "Atogepant, the first oral preventive treatment for chronic migraine",
author = "Haanes, {Kristian A.} and Lars Edvinsson",
year = "2023",
doi = "10.1016/S0140-6736(23)01462-9",
language = "English",
volume = "402",
pages = "748--749",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10404",
}
RIS
TY - JOUR
T1 - Atogepant, the first oral preventive treatment for chronic migraine
AU - Haanes, Kristian A.
AU - Edvinsson, Lars
PY - 2023
Y1 - 2023
U2 - 10.1016/S0140-6736(23)01462-9
DO - 10.1016/S0140-6736(23)01462-9
M3 - Comment/debate
C2 - 37516124
AN - SCOPUS:85168978485
VL - 402
SP - 748
EP - 749
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10404
ER -
ID: 397603804